Recombinant Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag, 100 µg

Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Source
Recombinant Cynomolgus / Rhesus macaque BCMA protein, Fc Tag (BCA-C5253) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 53 (Accession # A0A2K5UD97-1). In the region Met 1 - Ala 53, the AA sequence of Cynomolgus and Rhesus macaque BCMA are homologus.
Predicted N-terminus: Met 1

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 32.1 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy"
Al Hadidi, Szabo, Esselmann et al
Bone Marrow Transplant (2022)
(2)  "Dose-response correlation for CAR-T cells: a systematic review of clinical studies"
Rotte, Frigault, Ansari et al
J Immunother Cancer (2022) 10 (12)
(3)  "A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count"
Wang, Tsao, Gu et al
J Transl Med (2022) 20 (1), 608
Showing 1-3 of 1001 papers.